California wants to cap drug prices, but Big Pharma isn't having it. Amid growing backlash over drug pricing, companies such as Johnson & Johnson and Bristol-Myers Squibb are funneling millions of dollars into stamping out a new proposal that would curb drug spending in the state.
Major oncology groups, including the American Society of Clinical Oncology and the National Comprehensive Cancer Network, are working on tools to help size up the value that pricey new treatments provide. But in the meantime, some oncologists are increasingly avoiding prescribing meds that have little to no effect on cancers.
In the face of hefty hep C competition from Gilead and AbbVie, can Daklinza profit from a set of niche uses?
At Express Scripts, both Sanofi and Regeneron's Praluent and Amgen's Repatha scored a spot on the preferred formulary, which gives both PCSK9 products a chance to snare the pharmacy benefits manager's patients.
Pharma watchers know that price increases on drugs are a common occurrence. So why has it taken until now for one of pharma's go-to strategies to spark public outcry?
Want a surefire path to an Office of Prescription Drug Promotion (OPDP) warning letter? Leave side effects out of a drug promo, a new analysis says. As a team of Johnson & Johnson execs found, 60% of the FDA warning letters and untitled letters issued by OPDP between 2013 and 2015 cited pharma for omitting risk information in promotional materials.
Recently, Eli Lilly and Boehringer Ingelheim's Jardiance became the first diabetes drug to show it could reduce the combined risk of heart attack, stroke and death from cardiovascular causes--doing so by 14% in a study of high-risk Type 2 diabetes patients. But payers aren't exactly running to redo their formularies.
Roche has been facing pricing pushback for its breast cancer drug Kadcyla in the U.K., with the country's cost watchdog nixing the med last year and the Cancer Drugs Fund recently rejecting it from its covered list. Now, patients are voicing their discontent, calling on Britain's health minister to override the company's Kadcyla patents and open the door for lower-priced copies.
Roche's experimental therapy, ocrelizumab, recently posted positive Phase III data in patients with primary progressive multiple sclerosis, a less common form of the disease--affecting about 10% to 20% of sufferers--that right now remains untreated.
New oral anticoagulants--such as Johnson & Johnson's Xarelto and Boehringer Ingelheim's Pradaxa--have been in fierce competition with one another for awhile now. But they still have a ways to go to displace the old-guard therapy warfarin--and one GlobalData analyst thinks she knows why.